dpx-survivac

Vaccineexperimental

Clinical trial activity

10 trials · 5 clinical orgs · 0 marketing orgs

Phase 1
4
Phase 2
6
Phase 3
0
Phase 4
0

Earliest trial started Dec 1, 2011 (NCT01416038)

Timeline

2010s

  1. Jan 1, 2011

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2015

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • dpx-survivac

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05243524Phase 2Aug 5, 2022ImmunoVaccine Technologies, Inc.
NCT04895761Phase 1Sep 10, 2021Providence Health & Services
NCT04920617Phase 2Jun 18, 2021ImmunoVaccine Technologies, Inc., Merck
NCT03836352Phase 2Dec 21, 2018ImmunoVaccine Technologies, Inc., Merck
NCT03349450Phase 2Mar 13, 2018ImmunoVaccine Technologies, Inc., Merck, University of Toronto
NCT03029403Phase 2Mar 13, 2017ImmunoVaccine Technologies, Inc., Merck, University of Toronto
NCT02785250Phase 1Apr 1, 2016ImmunoVaccine Technologies, Inc., Incyte
NCT02323230Phase 2Jan 1, 2015ImmunoVaccine Technologies, Inc.
NCT03332576Phase 1Aug 23, 2013ImmunoVaccine Technologies, Inc.
NCT01416038Phase 1Dec 1, 2011ImmunoVaccine Technologies, Inc.
Showing 10 of 10 trials
Page 1 / 1

Organizations

Research & Development (5)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
ImmunoVaccine Technologies, Inc.For profit9722011
MerckFor profit4012017
University of TorontoAcademic/Hospital2212017
IncyteFor profit1012016
Providence Health & ServicesAcademic/Hospital1112021
5 organizations
Page 1 / 1